Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CING | US
-0.15
-2.67%
Healthcare
Biotechnology
30/06/2024
24/04/2026
5.47
5.70
5.85
5.42
Cingulate Inc. a clinical-stage biopharmaceutical company focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate) which is in phase 3 clinical trial and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children adolescents and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City Kansas.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
71.5%1 month
67.3%3 months
121.1%6 months
98.3%-
-
4.53
0.11
0.06
-0.36
-
-
-18.05M
16.65M
16.65M
-
-
-
-
-1.36K
0.05
0.95
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.52
Range1M
1.81
Range3M
7.09
Rel. volume
0.99
Price X volume
2.26M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| PLUR | PLUR | Biotechnology | 3.345 | 18.30M | -2.76% | n/a | 30845.83% |
| DOMH | DOMH | Biotechnology | 2.89 | 18.14M | 0.00% | n/a | 7.66% |
| DarT Bioscience Inc | DARE | Biotechnology | 2.11 | 18.03M | -0.47% | 0.12 | 218.34% |
| Can-Fite BioPharma Ltd | CANF | Biotechnology | 2.91 | 17.74M | 0.00% | n/a | 0.00% |
| ICU | ICU | Biotechnology | 4.13 | 17.31M | -2.59% | n/a | -45.50% |
| HCW Biologics Inc. Common Stock | HCWB | Biotechnology | 0.3756 | 16.39M | -8.23% | n/a | -159.13% |
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 0.5939 | 16.07M | 4.19% | n/a | 1.90% |
| Aytu BioScience Inc | AYTU | Biotechnology | 2.52 | 15.50M | 0.00% | n/a | 54.59% |
| iBio Inc | IBIO | Biotechnology | 1.68 | 15.35M | -7.18% | n/a | 20.92% |
| Lexaria Bioscience Corp | LEXX | Biotechnology | 0.9438 | 14.92M | 0.10% | n/a | 1.41% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.36 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.53 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 121.08 | 72.80 | Riskier |
| Debt to Equity | 0.11 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 16.65M | 3.66B | Emerging |